Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Speciﬁcally, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.
At Xontogeny, we believe that scientific founders supply the passion and determination integral to the success of their companies. While the foundation of success is good science, how that science is developed from inception to maturity serves as the critical pathway. Therefore, we focus on supporting the entrepreneur’s pursuit and optimizing the development pathway with an exceptionally talented and experienced operational team. With our team’s track record of success, entrepreneurs of affiliated companies will gain the support and guidance they need while remaining lean, virtual, and without the financial burden of supporting a full-time team.
This dynamic model has the additional benefit of supporting the goals of the founding scientists and entrepreneurs to retain more control and equity, while increasing the chance of accessing investment, and ultimately development success.
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group to their healthcare practice group.
Joseph Edelman founded Perceptive Advisors, LLC in 1999, a hedge fund focused on supporting the progress of the life sciences industry. Under Joe’s leadership, Perceptive has grown into one of the largest and most successful life sciences funds with over $2 billion of assets under management by applying thorough due diligence and insights in assessing technologies for investment. The firm oversees a portfolio of investments in various therapeutic areas across all stages of development and commercialization. Perceptive has increasingly led seed and early financing rounds in private life sciences companies from company formation through the development life cycle. Previously, Joe was Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from 1994 through 1998. Prior to Aries Fund, he was Senior Biotechnology Analyst at Prudential Securities for four years, after starting his career in the healthcare sector of the securities industry as Biotechnology Analyst at Labe, Simpson. Joe earned an MBA from New York University and a BA, magna cum laude, in psychology from the University of California, San Diego.
Adam Stone joined Perceptive Advisors, a hedge fund focused on supporting the progress of the life sciences industry, in 2006. Previously, he served as Senior Analyst at Ursus Capital. Adam earned his BA degree in molecular biology from Princeton University. Over the last decade, Mr. Stone has helped to grow Perceptive into a multi-billion dollar asset management firm, and internally led the formation of the Perceptive Credit Opportunities Fund. He has played an integral role in the development of several early stage biotech and healthcare companies, currently serving on the boards of Solid Biosciences and Renovia.